The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses.

Neoplasia : an International Journal for Oncology Research
Bipasha MukherjeeSandeep Burma

Abstract

Inhibitors of PI3K/Akt signaling are being actively developed for tumor therapy owing to the frequent mutational activation of the PI3K-Akt-mTORC1 pathway in many cancers, including glioblastomas (GBMs). NVP-BEZ235 is a novel and potent dual PI3K/mTOR inhibitor that is currently in phase 1/2 clinical trials for advanced solid tumors. Here, we show that NVP-BEZ235 also potently inhibits ATM and DNA-PKcs, the two major kinases responding to ionizing radiation (IR)-induced DNA double-strand breaks (DSBs). Consequently, NVP-BEZ235 blocks both nonhomologous end joining and homologous recombination DNA repair pathways resulting in significant attenuation of DSB repair. In addition, phosphorylation of ATMtargets and implementation of the G(2)/M cell cycle checkpoint are also attenuated by this drug. As a result, NVP-BEZ235 confers an extreme degree of radiosensitization and impairs DSB repair in a panel of GBM cell lines irrespective of their Akt activation status. NVP-BEZ235 also significantly impairs DSB repair in a mouse tumor model thereby validating the efficacy of this drug as a DNA repair inhibitor in vivo. Our results, showing that NVP-BEZ235 is a potent and novel inhibitor of ATM and DNA-PKcs, have important implications for ...Continue Reading

Citations

Nov 13, 2013·Proceedings of the National Academy of Sciences of the United States of America·Donald S KirkpatrickKlaus P Hoeflich
Dec 19, 2013·PloS One·Laura B KleimanKevin M Haigis
Oct 19, 2014·Journal of the National Cancer Institute·Philip WongDian Wang
Dec 4, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ipsita PalMahitosh Mandal
May 5, 2016·Scientific Reports·Paula Maria Quaglio BelloziAntônio Carlos Pinheiro de Oliveira
Mar 13, 2017·Arthritis Research & Therapy·Daniel Toro-DomínguezMarta E Alarcón-Riquelme
Feb 26, 2019·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·V Krishnan Ramanujan
Mar 29, 2014·Breast Cancer : Basic and Clinical Research·Sebastian KugerCholpon S Djuzenova
Apr 12, 2017·Frontiers in Immunology·Tünde SzatmáriKatalin Lumniczky
Jan 15, 2013·Antioxidants & Redox Signaling·Joy N KavanaghKevin M Prise
Jan 15, 2015·Neurosurgical Focus·Imad Saeed Khan, Moneeb Ehtesham
Nov 27, 2014·Frontiers in Oncology·Akari MinamiSatoru Matsuda
Jun 21, 2014·Future Oncology·Mark R KelleyMelissa L Fishel
Nov 26, 2014·Annual Review of Medicine·Michael Goldstein, Michael B Kastan
Mar 4, 2014·Expert Opinion on Pharmacotherapy·Eilin AustreidHans Petter Eikesdal
Apr 8, 2014·Nature Communications·Nozomi TomimatsuSandeep Burma
Apr 13, 2017·Expert Opinion on Drug Discovery·Robert Musiol
Dec 15, 2017·Cell Death and Differentiation·Charbel DaridoStephen M Jane
Feb 20, 2018·Molecular Cancer·Khushwant S BhullarH P Vasantha Rupasinghe
Dec 5, 2019·Frontiers in Pharmacology·Paula Maria Quaglio BelloziAntônio Carlos Pinheiro de Oliveira

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Ataxia telangiectasia

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.